- Morgan Stanley reaffirmed its “Overweight” rating for Natera (NASDAQ:NTRA), with a price target increase from $185 to $195.
- Natera’s stock experienced a 17% surge in morning trading following strong second-quarter financial results, closing with a 7.7% gain.
- The company’s market capitalization stands at approximately $20.75 billion, highlighting its significant role in the genetic testing industry.
Natera (NASDAQ:NTRA) is a genetic testing company that specializes in non-invasive prenatal testing, oncology, and organ transplant rejection assessment. The company is known for its innovative approach to genetic testing, providing valuable insights for healthcare providers and patients. Natera competes with other genetic testing companies like Illumina and Myriad Genetics, striving to maintain its position in the rapidly growing genetic testing market.
On August 10, 2025, Morgan Stanley reaffirmed its “Overweight” rating for Natera, with the stock priced at $151.95. This rating suggests that Morgan Stanley expects Natera’s stock to outperform the average market return. The investment bank also increased its price target for Natera from $185 to $195, indicating a positive outlook for the company’s future performance.
Natera’s stock experienced a notable surge, climbing as much as 17% in morning trading following the announcement of strong second-quarter financial results. The company exceeded expectations, which led to an increase in investor confidence. By the end of the trading day, Natera’s stock closed with a 7.7% gain, reflecting a $10.87 increase in its price.
The stock’s price fluctuated between a low of $151.84 and a high of $165.09 during the day. Over the past year, Natera’s stock has reached a high of $183 and a low of $110.57, showcasing its volatility. With a market capitalization of approximately $20.75 billion, Natera remains a significant player in the genetic testing industry.
Natera’s trading volume for the day was 3,849,580 shares, indicating strong investor interest. The company’s decision to raise its full-year revenue forecast further bolstered investor confidence, contributing to the stock’s positive performance. As Natera continues to innovate and expand its offerings, it remains a key player in the genetic testing market.
